Trial Profile
Phase I Trial of Ixabepilone and Vorinostat in Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixabepilone (Primary) ; Vorinostat (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Pharmacokinetics
- 01 Nov 2019 Status changed from active, no longer recruiting to completed.
- 30 Aug 2019 Planned End Date changed from 1 Jun 2019 to 3 Jun 2020.
- 04 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Jun 2019.